Form 4: MAIA Biotechnology Director Acquires Stock Options

Director Steven M. Chaouki acquired 5,728 stock options in MAIA Biotechnology, Inc. on June 30, 2024.

Summary

• Steven M. Chaouki, a director of MAIA Biotechnology, Inc., filed a Form 4 on July 2, 2024, reporting a transaction.
• On June 30, 2024, Chaouki acquired 5,728 stock options with an exercise price of $3.42.
• These options, granted under the company's 2021 Equity Incentive Plan, vest immediately and are exercisable from the grant date.
• The options expire on June 30, 2034.
• Following the transaction, Chaouki directly owns 5,728 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of aligning management interests with shareholders, but it's not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• Immediate vesting of the options could incentivize the director to contribute to the company's success.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the director's performance leads to an increase in the company's stock price.

Key Dates